drugset / Trial / NCT01289886
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
RandomizedParallel-groupDouble-blind
Summary
The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic (PK/PD) of ascending single oral dose of BR-A-657 in healthy male subjects.
Timeline
- Start
- 2003-09
- Primary completion
- 2003-11
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FIMASARTAN POTASSIUM TRIHYDRATE | Unknown | 20 mg | Oral |
| Subject | FIMASARTAN POTASSIUM TRIHYDRATE | Unknown | 60 mg | Oral |
| Subject | FIMASARTAN POTASSIUM TRIHYDRATE | Unknown | 120 mg | Oral |
| Subject | FIMASARTAN POTASSIUM TRIHYDRATE | Unknown | 240 mg | Oral |
| Subject | FIMASARTAN POTASSIUM TRIHYDRATE | Unknown | 360 mg | Oral |
| Subject | FIMASARTAN POTASSIUM TRIHYDRATE | Unknown | 480 mg | Oral |